Viral vectors for the treatment of retinal dystrophy

Patent metadata

Field	Value
Publication number	US-9163259-B2
Application number	US-201313873558-A
Country	US
Kind code	B2
Filing date	Apr 30, 2013
Priority date	May 4, 2012
Publication date	Oct 20, 2015
Grant date	Oct 20, 2015

Abstract

The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.

First claim

The invention claimed is:

1. A viral vector comprising:
a vector genome comprising a retinaldehyde binding protein 1 (RLBP1) coding sequence comprising nucleic acid sequences in the 5′ to 3′ direction of: SEQ ID NO: 36, 62, 63, 64, 65, 66, 1, 3, 4, 5, 6, 8, and 9, and
an adeno-associated virus (AAV) serotype 2 or 8 capsid.

2. The viral vector of claim 1 , wherein said vector comprises an adeno-associated virus (AAV) serotype 8 capsid.

3. A composition comprising the viral vector of claim 1 .

4. The composition of claim 3 further comprising a pharmaceutically acceptable excipient.

5. A viral vector comprising:
an adeno-associated virus (AAV) serotype 2 or 8 capsid,
a vector genome comprising a retinaldehyde binding protein 1 (RLBP1) coding sequence comprising, in the 5′ to 3′ direction, nucleic acid sequences selected from the group consisting of:
a) SEQ ID NO: 2, 10, 5, 6, 8, and 9;
b) SEQ ID NO: 2, 11, 5, 6, 8, 14, 9;
c) SEQ ID NO: 2, 22, 5, 6, 8, 23, and 9; and
d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23, and 9.

6. A nucleic acid comprising a gene cassette, said gene cassette comprises, in the 5′ to 3′ direction:
(i) a 5′ inverted terminal repeat (ITR) having a nucleic acid sequence of SEQ ID NO: 2 or a non-resolvable ITR having a nucleic acid sequence of SEQ ID NO: 1;
(ii) a recombinant nucleotide sequence comprising an RLBP1 coding sequence having a promoter nucleic acid sequence selected from: SEQ ID NO: 3, 10, 11, 12 and 22 operably linked to said RLBP1 coding sequence; and
(iii) a 3′ITR having a nucleic acid sequence of SEQ ID NO: 9.

7. The nucleic acid of claim 6 that is a plasmid.

8. The nucleic acid of claim 6 , further comprising the nucleic acid sequence selected from SEQ ID NO: 26, 27, 28, 29, 30 and 50.

9. The nucleic acid of claim 6 , wherein the gene cassette comprises, in the 5′ to 3′ direction, the sequences selected from:
a) SEQ ID NO: 2, 10, 5, 6, 8, and 9,
b) SEQ ID NO: 2, 11, 5, 6, 8, 14 and 9,
c) SEQ ID NO: 2, 22, 5, 6, 8, 23 and 9,
d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23 and 9, and
e) SEQ ID NO: 1, 3, 4, 5, 6, 8, and 9.

Assignees

• Choi Vivian
• Bigelow Chad Eric
• Dryja Thaddeus Peter
• Police Seshidhar Reddy
• Novartis Ag

Inventors

• Choi Vivian
• Bigelow Chad Eric
• Dryja Thaddeus Peter
• Police Seshidhar Reddy

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• C12N2750/14371

  Demonstrated in vivo effect · CPC title

• A61K38/1709

  from mammals · CPC title

• A61K48/005

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title